DLBCL treatment has gotten more complicated Back in my day it was RCHOP if relapse salvage and ASCT

New paper out: “Prevalence of & Risk Factors for Depression, Anxiety & Burnout in U.S. Neurosurgery Residents.” The data are clear—mental health challenges in neurosurgery training are common and consequential. It’s time to treat resident wellness like we treat aneurysms and

Strong data in metastatic ccRCC after prior PD-1 therapy 📊 • Lenvatinib + Everolimus vs Cabozantinib • PFS 15.7 vs 10.2 months (HR 0.51, p=0.02) • ORR 52.6% vs 38.6% • 1-year OS ~87% vs ~84.6% (immature) • Discontinuation for toxicity 20% vs 10.9% These results help guide

@KidneyCancer

Our clinical trial testing CD70 targeting CAR NK cells for clear cell kidney cancer that has progressed on standard treatment is now open @MDAndersonNews ! Info: https://t.co/OcJw7m0HER @kidneycan @PavlosMsaouel @DrChoueiri @NazliDizman @OncHahn

Big day for a rare disease 🎉🧬 The new NCCN Guidelines for Appendiceal Cancer just dropped — and they’re fantastic. For the first time, this rare and often misunderstood disease finally gets its own dedicated guidance, instead of the old “just follow colorectal cancer”

Thank you @kyleconcannonMD @Cracking_Cancer for the opportunity to discuss testicular cancer detection and treatment! @MDAndersonNews

So proud of @MDAndersonNews #radonc resident @adam_grippin for his FIRST AUTHOR NATURE PAPER w/ mentor @StevenLin_MDPhD Bc of all the media- non-medical folks in my life have asked me about it & can’t believe I know the genius behind this work! 🤩 https://t.co/GCZH6tTtDJ

🚨Our new paper is out today in Nature! We show that SARS-CoV-2 mRNA vaccines can sensitize tumors to immune checkpoint blockade (ICI) — revealing that clinically available RNA vaccines may act as potent immune modulators.

One of many highlights this year! Great session #GU25

🙏Honored to receive this prestigious recognition from @ASCO @ConquerCancerFd alongside brilliant colleagues! Grateful to my mentors, @DocMattCampbell & @OAlhalabiMD, & @MDAndersonNews family, for their support in rare GU cancer research throughout this journey to #EndCancer.

Tivozanib in heavily pretreated pts w/ clear cell RCC: retrospective analysis @mdandersonnews showed ORR 7.7%, PFS 3.8mos, benefit limited to pts w/ indolent disease and prolonged prior TKI therapy @andrewjohnsmd @docmattcampbell @pavlosmsaouel @onchahn https://t.co/eHvER1G6cw

⭐️Delighted to welcome Dr. Deepak Bhamidipati to our @SarahCannonDocs Early Phase Drug Development Unit in Nashville! 🎉 🌟 Recipient of the prestigious @ASCO YIA and Merit Awards, he will be a fantastic addition to our team @SCRIOncology @TheUSONetwork Nashville, TN ⭐️He

1/5 Excited to activate this week our fourth clinical trial designed for #RenalMedullaryCarcinoma (RMC). It will also separately enroll patients with epithelioid sarcoma, another rare but deadly cancer defined by loss of the SMARCB1 tumor suppressor: https://t.co/5MH7IkrUPp

👋This is Mohammad Jad, Postdoc. Fellow & Postdoc. Association Team Leader @MDAndersonNews, mentored by @DocMattCampbell & @OAlhalabiMD 👉Applying for #InternalMedicine Residency #Match2025 🙏Dreaming of becoming a humane #oncologist through purposeful science – excited to

🎊 Our Latest From #BoneMets Lab & Team, now in @CRC_AACR – Dr. Eleonora Dondossola and Dr. Matt Campbell of GU Oncology @MDAndersonNews Lead⭐️S. Maksimović @dr4gut1n👉TKI activity & efficacy (cabo, lenva, axi) in orthotopic mouse models of bone-metastatic ccRCC, studying 1⃣

I’m excited to present our work exploring whether #COVID #mRNA #vaccines could impact #immunotherapy outcomes. Big thanks to #ESMO2024 conference organizers for sponsoring my trip with a travel award and @MDAndersonNews for highlighting this project!

Of all the milestones our #RenalMedullaryCarcinoma research has achieved, this is definitely a highlight. Grateful to the many people who work tirelessly to help our patients.

1/5 Excited to share our @MsaouelLab clinical analysis of 135 patients with #RenalMedullaryCarcinoma treated @MDAndersonNews over 20 years 👉 https://t.co/3GHbQn2FK4 #endRMC #rarecancers @KidneyCancer @renalmedullary @RmcAlliance @RMCAwareness @RareCancerRF @thermcrf @kcCURE

Summary slide. CML response definitions @GCC_Cortes @FadiHaddad_MD #CML